Insiders Trades
Stoke Therapeutics, Inc. Stock: price and insider trades · United States
Stoke Therapeutics, Inc.: what insiders have been doing
Stoke Therapeutics, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 50 filings came from 11 insiders.
Only sales appear on the open market, 30 sales in all totalling €4.8M, filed by 7 insiders. The totals do not cover 1 filing with an undisclosed amount. The largest single trade was a sale of €1.1M by Krainer Adrian R., published on 12 March 2026.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 50 filings, this issuer sits above that mark. Since 2021, the database holds no purchases and 70 sales by insiders of the company. The 10-K for the year ended 31 December 2025 shows 184.4 m USD of revenue and -6.9 m USD of net income.
Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
140
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€122M
70 ops. · all time
Who traded when
BuySaleBarry Ticho22 sales
Jonathan Allan14 sales
Edward M. MD Kaye9 sales
Krainer Adrian R.4 sales
Skorpios Trust2 sales
Hoitt Jason1 sale
+2 other insiders
Analyst consensus: bullish or bearish?
Analysts rate Stoke Therapeutics, Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$46.46.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,454 of 24,148 companies
27.1
score / 100
Value42
Quality12
FCF yld2.9%
Earn yld-0.4%
EV/EBITDA·
ROE-61%
Gross mgn·
Net mgn-3.7%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$24.17
Analyst consensus
13 analystsStrong buy
US$35.00Target US$46.46(+92%)US$60.00
Income statement
RevenueUS$184.4M
EBITDA-US$18.8M-10% margin
Net income-US$6.9M-3.7% margin
Valuation
PER (forward)-6.9x
P/Book4.4x
Beta1.26
Balance sheet & cash
Market capUS$1.6B
Total debtUS$3M
Free Cash FlowUS$44.9M
Debt / Equity1%
Profitability & ownership
ROE-61.1%
ROA-35.9%
% insiders3.7%
% institutions125.4%
Last declaration on 2 October 2026
Declarations140 total
627 shares@ US$26.010.0010% mcap100.0% of flowCommonSEC144:0001950047-26-010004
627 shares@ US$26.330.0010% mcap1.0% of flowCommon StockSEC:0001966716-26-000014:0
1,051 shares@ US$26.15940.0017% mcap0.7% of flowCommon StockSEC:0001780088-26-000023:0
3,945 shares@ US$30.5120.0074% mcap3.1% of flowCommon StockSEC:0001780088-26-000021:0
1,600 shares@ US$31.05690.0030% mcap1.3% of flowCommon StockSEC:0001780088-26-000021:1
10,000 shares0Common StockSEC:0001780088-26-000019:0
4,525 shares@ US$32.00720.0089% mcap3.7% of flowCommon StockSEC:0001780088-26-000019:1
242 shares@ US$32.46810.0005% mcap0.2% of flowCommon StockSEC:0001780088-26-000019:2
6,000 shares0Common StockSEC:0001966716-26-000012:0
26,250 shares0Common StockSEC:0001522780-26-000007:0
11,930 shares@ US$32.00720.023% mcap13.6% of flowCommon StockSEC:0001522780-26-000007:1
637 shares@ US$32.46810.0013% mcap0.7% of flowCommon StockSEC:0001522780-26-000007:2
2,716 shares@ US$32.00720.0053% mcap5.4% of flowCommon StockSEC:0001966716-26-000012:1
145 shares@ US$32.46810.0003% mcap0.3% of flowCommon StockSEC:0001966716-26-000012:2
5,907 shares@ US$28.95010.011% mcap4.4% of flowCommon StockSEC:0001780088-26-000017:0
1,269 shares@ US$29.45390.0023% mcap1.0% of flowCommon StockSEC:0001780088-26-000017:1
20,967 shares@ US$28.860.037% mcap100.0% of flowCommonSEC144:0001950047-26-007565
6,728 shares@ US$32.6150.014% mcap5.8% of flowCommon StockSEC:0001780088-26-000015:0
500 shares@ US$33.26780.0010% mcap0.4% of flowCommon StockSEC:0001780088-26-000015:1
7,228 shares@ US$32.720.015% mcap100.0% of flowCommonSEC144:0001950047-26-006742
1,457 sharesCommon StockSEC:0001966716-26-000010:0
1,457 shares@ US$30.000.0022% mcap100.0% of flowCommonSEC144:0001950047-26-006194
1,838 shares@ US$32.661.6% of flowCommon StockSEC:0001780088-26-000009:0
8,692 shares@ US$33.63540.013% mcap18.0% of flowCommon StockSEC:0001966716-26-000008:0
601 shares@ US$34.40790.0010% mcap1.3% of flowCommon StockSEC:0001966716-26-000008:1
25 of 140 declarations
About Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. (ticker: STOK) is a U.S.-listed biotechnology company trading on the NASDAQ in the United States, with core operations centered in Bedford/Cambridge, Massachusetts. Founded in 2014, the company was co-founded by Adrian Krainer, Ph.D. and Isabel Aznarez, Ph.D. around a proprietary scientific approach called TANGO, designed to increase protein expression by modulating pre-mRNA splicing. That platform gives Stoke a differentiated profile within the rare-disease biotech universe, where targeted RNA-based approaches are increasingly competing with gene therapy, ASOs, and other precision-medicine modalities.
Stoke’s business model is built on developing disease-modifying medicines for severe genetic disorders by addressing the underlying biology rather than only managing symptoms. Its lead investigational program is zorevunersen (STK-001), being developed for Dravet syndrome, a severe and progressive genetic epilepsy. Management has consistently framed zorevunersen as the company’s first and most advanced clinical asset, and Stoke has also highlighted earlier-stage research efforts in dominant optic atrophy (ADOA) and SYNGAP1-related disorders. For investors, this means the company is still highly concentrated around one lead asset, but with a pipeline strategy aimed at creating optionality over time.
Read moreShow less
From a competitive standpoint, Stoke operates in a niche where scientific credibility, durability of clinical effect, and regulatory execution matter more than near-term revenue scale. The company’s collaboration with Biogen on zorevunersen is strategically important: it provides external validation, broader development support, and a pathway toward eventual commercialization, while also sharing development risk. In the rare epilepsy space, where patient populations are small but unmet need is high, successful differentiation depends on meaningful clinical benefit and a tolerable safety profile.
Geographically, Stoke is a U.S.-based company, but its late-stage development program is global in scope. The EMPEROR Phase 3 study has been conducted with recruitment in the U.S., the U.K., and Japan, underscoring the company’s intent to build an international regulatory package. Recent company updates in 2025 and 2026 emphasized continued progress in the Phase 3 program, long-term follow-up data from open-label extension studies, and increased focus on commercialization readiness. Those updates are important because they suggest Stoke is moving from a purely research-driven posture toward a more execution-oriented phase.
Recent SEC Form 4 insider transaction filings related to STOK also indicate ongoing insider activity, including sales executed under 10b5-1 plans. Such transactions are common in public biotech companies and should be read cautiously; they are worth monitoring, but they do not necessarily imply a change in the company’s fundamental outlook. Overall, Stoke Therapeutics remains a high-risk, high-upside U.S. biotech story on NASDAQ, with a distinctive RNA-medicine platform, a focused lead program, and material clinical and regulatory catalysts ahead.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
